First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100
Clinical trial NCT05426746 · COMPLETED
Trial details
- NCT number
- NCT05426746
- Sponsor
- Aqualung Therapeutics Corp.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-05
- Primary completion
- 2023-05-18
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.